Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $20.83.
A number of equities analysts have recently issued reports on AMPH shares. Piper Jaffray Companies set a $19.00 target price on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, October 22nd. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 27th. Jefferies Group set a $19.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. Raymond James Financial lowered shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective on the stock. in a report on Thursday, November 9th. Finally, BMO Capital Markets increased their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a report on Friday, November 10th.
In related news, CFO William J. Peters sold 6,226 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $19.67, for a total value of $122,465.42. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Stephen B. Shohet sold 7,862 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $19.25, for a total transaction of $151,343.50. Following the completion of the transaction, the director now owns 31,978 shares in the company, valued at $615,576.50. The disclosure for this sale can be found here. Insiders sold 67,058 shares of company stock worth $1,283,317 over the last 90 days. 11.10% of the stock is currently owned by company insiders.
Shares of Amphastar Pharmaceuticals (AMPH) traded down $0.25 during mid-day trading on Tuesday, hitting $18.78. 111,197 shares of the stock were exchanged, compared to its average volume of 161,555. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $19.95. The firm has a market capitalization of $863.43, a price-to-earnings ratio of 125.20, a price-to-earnings-growth ratio of 1.32 and a beta of 1.51. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.